Science meets art at The London Cancer Hub 20 Apr 2024 The ICR's Public Engagement Manager Mariana Campos reflects on a year of cultural activities at one of London’s most ambitious regeneration projects Find out more Show/Hide
FDA approval for capivasertib: and our new collaboration opportunities for industry partners 17 Nov 2023 The US Food and Drug Administration (FDA) has approved the AKT inhibiting drug capivasertib, now given the brand name Truqap, as a breast cancer treatment. Henry French introduces other current opportunities for industry partners to work with ICR researchers, including in the discovery and development of cancer drugs, and asks – could any become the next capivasertib? Find out more Show/Hide
Commercial partnering opportunities in oncology: a new biomarker test to guide treatment for oestrogen-receptor positive breast cancer 09 Feb 2023
Five reasons why pharma and biotech companies are co-locating with university researchers – and one more reason why you should too! 20 Apr 2022